LCG
ICPT

Lisanti Capital Growth’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Lisanti Capital Growth’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,225
Closed -$913K – 125
2013
Q3 		$913K Sell
13,225
-360
-3% -$17.8K 0.42% 90
2013
Q2 		$636K Buy
+13,585
New +$464K 0.3% 91

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Lisanti Capital Growth's ICPT Position: Q4 2013 in Review

Lisanti Capital Growth sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2013, closing a stake of 13,225 shares — an estimated $913K sold.

Lisanti Capital Growth first reported a position in ICPT in Q2 2013 and held it in 2 quarters. The position peaked at $913K in Q3 2013. 88 funds tracked by Wall St. Rank hold ICPT as of Q4 2013.

  • Lisanti Capital Growth reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2013 after selling out during the quarter.
  • Lisanti Capital Growth sold 13,225 Intercept Pharmaceuticals, Inc. shares in Q4 2013, an estimated $913K.
  • Lisanti Capital Growth first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 2 quarters.
  • Lisanti Capital Growth's Intercept Pharmaceuticals, Inc. position peaked at $913K in Q3 2013.
  • 88 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2013.

Based on Lisanti Capital Growth's 13F filing for Q4 2013, filed 29 Jan 2014.